However, T cells are also critical in protective immunity, especially in immunecompromised patients. In this study, we examined the association of T cell dysfunction, as marked by expression of T cell exhaustion molecules, and posttransplant infections in a cohort of liver transplant patients. We focused on Programmed Death 1 (PD-1) and T cell Ig-and mucin-domain molecule 3 (Tim-3), which are potent coinhibitory receptors, and their persistent expression often leads to T cell dysfunction and compromised protective immunity. We found that patients with the highest expression of PD-1 +Tim-3+ T cells in the memory compartment before transplantation had increased incidence of infections after liver transplantation, especially within the first 90 days. Longitudinal analysis in the first year showed a strong association between variability of PD-1 and Tim-3 expression by T cells and infectious episodes in transplant patients. Furthermore, T cells that expressed PD-1 and Tim-3 had a significantly reduced capacity in producing interferon (IFN)-γ in vitro, and this reduced IFN-γ production could be partially reversed by blocking PD-1 and Tim-3. Interestingly, the percentage of Foxp3+ regulatory T cells in liver transplant patients was stable in the study period. We concluded that the functional status of T cells before and after liver transplantation, as shown by PD-1 and Tim-3 expression, may be valuable in prognosis and management of posttransplant infections.
T cells are the principal targets of the commonly used immunosuppression drugs. However, T cells also play a central role in fighting against a plethora of pathogens. Thus, prolonged and nonspecific immunosuppression after LT may compromise patients' protective immunity, leaving patients vulnerable to infectious complications.
Indeed, transplant patients experience frequent infectious episodes, and sometimes life-threatening episodes. 5, 6 Evidence suggests that memory T cells, both central memory and effector memory T cells, are resistant to conventional immunosuppression, and therefore capable of mediating robust recall responses to fight many bacterial and viral organisms. 7, 8 However, their responses are tightly controlled by multiple regulatory mechanisms, and often acquire functionally different states, ranging from full-fledged effector cells to exhausted or dysfunctional cells. 7, 9 One of the interesting aspects in this spectrum involves the opposing roles of co-inhibitory and costimulatory receptors in the control of effector T cell responses.
10,11
Co-inhibitory molecules inhibit T cell activation and function by competing with co-stimulatory receptor ligands and interrupting downstream signaling from T cell receptors. 12 Sustained expression of multiple co-inhibitory receptors on T cells often marks exhausted T cells, which are frequently observed in chronic infections and cancer.
12-15
Programmed death 1 (PD-1) receptor, a member of the CD28 family, is a prominent inhibitory molecule suppressing T cell activation pathways upon binding to its ligands PD-L1 and PD-L2.
16
Increased PD-1 expression on T cells contributes to immune dysfunction and impaired clearance of viral infections, increased nosocomial infections, and cancer. 15, [17] [18] [19] T cell immunoglobulin and mucin-domain-containing molecule-3 (Tim-3), belonging to the phosphatidylserine receptor family, is another negative regulator of T lymphocytes. Tim-3 interacts with its ligand galectin-9 and utilizes a distinct pathway to inhibit T cell responses, leading to persistence of infections. [20] [21] [22] Patients with viral and alcoholic hepatitis are known to have immune dysfunctions affecting T cell responses against bacteria and viruses due to increased expression of coinhibitory receptors. 9, [23] [24] [25] In those settings, T cells that co-express immune inhibitory receptors PD-1 and Tim-3 become dysfunctional, with limited effector functions. 14, 25 Regulatory T (Tregs) cells are a subset of CD4+ T cells that express the transcription factor Foxp3; they have potent immunosuppressive properties and are critically involved in transplant survival. 26, 27 However, the suppressive properties of Tregs can also lead to persistence of antigens and are associated with decreased clearance of chronic infections such as hepatitis B and C. 28, 29 Additionally, there is increasing evidence that inhibitory molecules such as PD-1 may play a role in development of Tregs by altering the plasticity of Th1 cells, impairing cell-mediated immunity. 30, 31 In this study, we examined the dynamics of T cell co-inhibitory markers, T cell memory subsets, and Tregs in peripheral blood in a cohort of liver transplant patients. In this pilot longitudinal study involving pretransplant and posttransplant patient samples, we showed that T cells in the memory compartment with the highest expression of PD-1 and Tim-3 were dysfunctional. Importantly, sustained expression of such co-inhibitory markers post-LT was strongly associated with infectious complications.
| MATERIALS AND METHODS

| Subjects
Peripheral blood samples were prospectively collected at regular in- 
| Ethics statement
| Polychromatic flow cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient centrifugation, and stored in recovery cell culture media with 10% dimethylsulfoxide for phenotyping and functional experiments. The cell staining protocol and list of antibodies are described in Supplemental Materials and Methods.
Multicolor flow cytometry was performed on whole PBMCs using an LSRII instrument (BD Cytometry Systems, San Jose, CA). All data were analyzed by using Flow Jo Version 10 (Ashland, OR).
| Enzyme-linked immunosorbent assay (ELISA)
PBMCs were incubated with LEAF™ anti-human Tim-3 antibody and LEAF™ anti-human PD-1 antibody (10 μg/mL, BioLegend, San Diego, CA) or control IgG for 1 hour, followed by stimulation with anti-CD3
antibody (50 ng/mL, OKT3, BioLegend) and anti-CD28 antibody (2 μg/ mL, BD Biosciences, San Jose, CA) for 48 hours and 72 hours. Cell supernatant was subjected to ELISA analysis for quantitative detection of interferon (IFN)-γ according to manufacturer manuals (ThermoFisher Scientific, Waltham, MA). The optical density at 450 nm was measured using an ELISA reader (Synergy H4; BioTek, Winooski, VT). Linear mixed models were used to assess the changes over time of inhibitory markers within and between the patient groups. The time factor for the models was set at days 0, 30, 180, and 365. Post hoc marginal pairwise comparisons were performed to determine the adjusted means (95% confidence intervals) of changes in each marker of interest from day 0 to day 365. Spearman's correlation test was performed to determine the correlation between cytokine production and inhibitory markers at each time point. Box plots and line graphs were used to depict the distribution at different time points of markers and their trend over time.
| Statistics
All analyses were performed using Stata version 14.2 (StataCorp LP, College Station, TX), GraphPad Prism 7.0 (La Jolla, CA), and a P < .05 was considered statistically significant. (Table S1 ).
| RESULTS
| Patient enrollment
Patients presenting with signs and symptoms of infections un- 
| Characteristics of memory T cell subsets after LT
We prospectively collected PBMC samples in a longitudinal fashion from patients undergoing liver transplant at set time points. The Three patients in the infection group and 1 patient in the no-infection group had rejection episodes requiring increased immune suppression management between 6 and 9 mo post-LT. IE, infectious episode; CXR, chest x-ray; LOS, length of hospital stay; LT, liver transplantation; MRSA, methicillin-resistant Staphylococcus aureus; PCR, polymerase chain reaction.
(total median proportions for all patients, n = 16: pre-LT 7.4%, 1 month 15%, 6 months 15.6%, and 12 months 11.1%; median values). When the patient groups were compared longitudinally, the proportional distribution of the memory subsets remained stable with no difference between the groups ( Figure 1C ).
In CD4+ T cells, the overall median proportion of T CM was 43% and T EM was 9.8% pre-LT (n = 16), with central memory being the dominant memory subset at all time points. When the baseline proportions of the 2 patient groups (infection, INF and no infection, NI) compared to HC, the distribution of CD4+ T CM was similar ( Figure 1D ). On longitudinal analysis of patient groups, there was no difference in the distribution of T CM over time after transplantation ( Figure 1E ). However, NI had significantly higher median proportions of CD4 T EM compared to INF at the baseline pre-LT time point, but there were no differences over time after transplantation.
Overall, the proportion and distribution of T CM versus T EM were maintained after LT in both the CD8 and the CD4 compartments.
F I G U R E 1 Distribution of circulating CD4
+ and CD8 + memory T cell subsets after LT. A, Gating strategy of peripheral blood mononuclear cells from LT patients is shown. Lymphocytes were identified by scatter properties and viable CD3+ lymphocytes were divided into CD4+ and CD8+ T cell subsets. B and D, Representative flow plot shows gating strategy to identify CD8 memory subsets (B) and CD4 memory subsets (D). Central memory (CCR7+ CD45RO+, CM) and effector memory (CCR7-CD45RO+) percentages were compared between pretransplant data points of LT patients and healthy controls (HC, n = 5) on CD8 T cells (B) and on CD4 T cells (D). LT patients (n = 16) were divided into INF (n = 11, patients who developed infections after LT) and NI (n = 5, patients without infections after LT). Horizontal lines indicate median values and interquartile range (IQR) (Kruskal-Wallis test). CM, central memory; EM, effector memory. C and E, Proportion of memory subsets on CD8 (C) and CD4 (E) was computed for each patient over time based on CCR7 and CD45RO at 4 time points. We compared pretransplant baseline sample of each patient and post LT samples obtained at 30 days, 180 days, and 365 days using linear mixed models. Box plots show median ± IQR *P < .05 was considered statistically significant. CM, central memory; EM, effector memory; LT, liver transplantation 
| Pretransplant expression of PD-1 and Tim-3 is associated with infectious episodes after LT
We compared the expression of co-inhibitory molecules on T cell memory subsets pretransplantation in patients undergoing LT. We We also studied the differences in CD4+ T cell memory subsets among groups. The median percentages of PD-1 + Tim-3 + DP cells in CD4+ T cells were compared between the 2 patient groups and HC ( Figure 2C ). In CD4+ T EM , the median percentage of DP cells was 3.6% 
| Patients with increased expression of PD-1 and Tim-3 after LT experience increased infectious episodes
We did longitudinal assessments of PD-1 and Tim-3 expression over time after transplant to examine the progression of these markers in relation to transplantation. A total of 4 samples were collected from each patient including the pretransplant blood sample. We examined percentages of PD-1 and Tim-3 over time in the first year after LT and analyzed using linear mixed models on both CD4+ and CD8+ T cells. In CD8+ T EM cells, PD-1 + Tim-3 + cells continued to be significantly higher in the INF group than the NI group in the first year after LT. There was no marked difference in PD-1 and Tim-3 expression between the patient groups by day 365 ( Figure 3A) . The overall median expression of the co-inhibitors was low by day 365, which was ≈3% in both groups. Of note, most infections occurred in the first 3-6 months after LT in the patient cohort. The differences were less pronounced in the CD8+ T CM subset with higher PD-1 and Tim-3 expression in INF group at day 30 and day 180, but the differences in groups did not achieve statistical significance. In this longitudinal analysis, the co-inhibitor expression was higher at day 30 after LT both on CD4+ central and effector memory cells 
| Cytokine profiles in patients with high PD-1 and Tim-3 expression after LT
We assessed the functional status of CD4+ and CD8+ T cell memory subsets in LT patients by staining for expression of effector cytokines, as well as the cytolytic marker CD107α. PBMCs from patients were rested overnight, briefly stimulated with phorbol myristate acetate/ ionomycin, then stained for memory markers, followed by intracellular staining for cytokines. Healthy control cells processed under identical conditions or unstimulated PBMCs for each patient were included as controls.
As shown in Figure 5 , 
| DISCUSSION
In the present study, we focused on a cohort of LT patients and examined the expression of T cell co-inhibitory molecules in relation to infectious episodes after LT. We demonstrated that patients with high expression of the co-inhibitory molecules PD-1 and Tim-3 before transplantation had a strong tendency to develop infections after LT. increased co-inhibitory markers on memory CD8+ T cells are also associated with a dysfunctional state, resulting in inability to clear pathogens and development of chronic diseases. 16, 42, [44] [45] [46] What caused the high and sustained expression of PD-1 and Tim-3 on T cells, especially in patients before transplantation, was not examined in the present study, and therefore remains unknown.
However, the primary liver diseases (eg, hepatitis C infections), or history of infections, medications, and vaccinations may be contributing factors. However, some LT patients in our studies who were trans- is easily accessible and measurable, with infectious episodes both before and after transplant, is of potential diagnostic or prognostic values in the clinic. Currently, most institutions manage transplant patients with broad immune suppression protocols, which are associated with increased incidence of infections in the first year after transplantation. 4 Our data suggest that an early assessment of markers of T cell exhaustion pretransplantation may help identify patients at risk for infections, so that immunosuppression treatments can be adjusted and management of potential infections be considered. Also, measurements of T cell inhibitory markers posttransplantation may be useful in predicting risks of infections following LT. This personalized approach according to the patient's immune status is an emerging area in management of morbidity and mortality in susceptible patients.
This study also has limitations including a small sample size and challenges in obtaining adequate quantity of blood lymphocytes consistently from immunosuppressed patients at all time points. The patient samples are also biased toward certain racial groups in our study. Hence, it remains unknown whether race has any influence on expression of these markers. Though the immunosuppression regimen was uniform among all patients during the study period, the tacroli- Nevertheless, considering the strong association we identified and the negative impact of infections on LT outcomes, further studies based on multicenter and longitudinal settings will be required in moving the field forward.
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